MIR31HG and metabolic disease: Thus, MIR31HG may serve as a molecular target for metabolic diseases at least partially through suppression of FABP4. However, during the adipocyte differentiation, the expression of MIR31HG was transiently upregulated in the early stage (day 2) and returned to normal levels in the late stage (day 6).